Literature DB >> 19383376

Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.

Amir A Jazaeri1.   

Abstract

BRCA1 and BRCA2 germline mutations account for the majority of hereditary ovarian cancers and comprise 10% of total cases. Ovarian cancers arising from these mutations exhibit both overlapping and distinct clinical and molecular features. The expression profiles of sporadic ovarian cancers show similarities to those of BRCA1 and BRCA2-related tumors suggesting that BRCA-related pathways may be involved in their development as well. The purpose of this review is to consider the available data on ovarian cancers in the context of other investigations of BRCA-related transcriptional alterations, and highlight areas for future research.

Entities:  

Mesh:

Year:  2009        PMID: 19383376      PMCID: PMC5527878          DOI: 10.1016/j.molonc.2009.01.001

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  46 in total

1.  Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway.

Authors:  Zehua Wang; Min Li; Shi Lu; Yuan Zhang; Hongbo Wang
Journal:  Cancer Biol Ther       Date:  2006-03-05       Impact factor: 4.742

2.  Improved survival in BRCA2 carriers with ovarian cancer.

Authors:  Tuya Pal; Jenny Permuth-Wey; Rachna Kapoor; Alan Cantor; Rebecca Sutphen
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

3.  Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.

Authors:  Kelvin Y K Chan; Hilmi Ozçelik; Annie N Y Cheung; Hextan Y S Ngan; Ui-Soon Khoo
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

4.  The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.

Authors:  Roger L Milne; Ana Osorio; Teresa Ramón Y Cajal; Ana Vega; Gemma Llort; Miguel de la Hoya; Orland Díez; M Carmen Alonso; Conxi Lazaro; Ignacio Blanco; Ana Sánchez-de-Abajo; Trinidad Caldés; Ana Blanco; Begoña Graña; Mercedes Durán; Eladio Velasco; Isabel Chirivella; Eva Esteban Cardeñosa; María-Isabel Tejada; Elena Beristain; María-Dolores Miramar; María-Teresa Calvo; Eduardo Martínez; Carmen Guillén; Raquel Salazar; Carlos San Román; Antonis C Antoniou; Miguel Urioste; Javier Benítez
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

5.  EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer.

Authors:  Luke Hughes-Davies; David Huntsman; Margarida Ruas; Francois Fuks; Jacqueline Bye; Suet-Feung Chin; Jonathon Milner; Lindsay A Brown; Forrest Hsu; Blake Gilks; Torsten Nielsen; Michael Schulzer; Stephen Chia; Joseph Ragaz; Anthony Cahn; Lori Linger; Hilal Ozdag; Elena Cattaneo; E S Jordanova; Edward Schuuring; David S Yu; Ashok Venkitaraman; Bruce Ponder; Aidan Doherty; Samuel Aparicio; David Bentley; Charles Theillet; Chris P Ponting; Carlos Caldas; Tony Kouzarides
Journal:  Cell       Date:  2003-11-26       Impact factor: 41.582

6.  Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.

Authors:  Anna Potapova; Amanda M Hoffman; Andrew K Godwin; Tahseen Al-Saleem; Paul Cairns
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

7.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Authors:  Mary-Claire King; Joan H Marks; Jessica B Mandell
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

8.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.

Authors:  Amir A Jazaeri; Cindy J Yee; Christos Sotiriou; Kelly R Brantley; Jeff Boyd; Edison T Liu
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

9.  Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities.

Authors:  Joshua Z Press; Alessandro De Luca; Niki Boyd; Sean Young; Armelle Troussard; Yolanda Ridge; Pardeep Kaurah; Steve E Kalloger; Katherine A Blood; Margaret Smith; Paul T Spellman; Yuker Wang; Dianne M Miller; Doug Horsman; Malek Faham; C Blake Gilks; Joe Gray; David G Huntsman
Journal:  BMC Cancer       Date:  2008-01-22       Impact factor: 4.430

10.  Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family.

Authors:  D Gareth Evans; Andrew Shenton; Emma Woodward; Fiona Lalloo; Anthony Howell; Eamonn R Maher
Journal:  BMC Cancer       Date:  2008-05-30       Impact factor: 4.430

View more
  7 in total

1.  Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers.

Authors:  Chang K Sung; Dawei Li; Erik Andrews; Ronny Drapkin; Thomas Benjamin
Journal:  Mol Oncol       Date:  2012-12-12       Impact factor: 6.603

2.  BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Authors:  Pierosandro Tagliaferri; Monica Ventura; Francesco Baudi; Iole Cucinotto; Mariamena Arbitrio; Maria Teresa Di Martino; Pierfrancesco Tassone
Journal:  J Ovarian Res       Date:  2009-10-13       Impact factor: 4.234

Review 3.  Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease.

Authors:  Amir A Jazaeri
Journal:  Mol Oncol       Date:  2009-02-07       Impact factor: 6.603

Review 4.  Update on immune checkpoint inhibitors in gynecological cancers.

Authors:  Valerie Heong; Natalie Ngoi; David Shao Peng Tan
Journal:  J Gynecol Oncol       Date:  2016-12-14       Impact factor: 4.401

Review 5.  Nuclear microenvironment in cancer: Control through liquid-liquid phase separation.

Authors:  Ryu-Suke Nozawa; Tatsuro Yamamoto; Motoko Takahashi; Hiroaki Tachiwana; Reo Maruyama; Toru Hirota; Noriko Saitoh
Journal:  Cancer Sci       Date:  2020-07-21       Impact factor: 6.716

6.  Circulating Tumor Cells Enumerated by a Centrifugal Microfluidic Device as a Predictive Marker for Monitoring Ovarian Cancer Treatment: A Pilot Study.

Authors:  Hyera Kim; Minji Lim; Jin Young Kim; So-Jin Shin; Yoon-Kyoung Cho; Chi Heum Cho
Journal:  Diagnostics (Basel)       Date:  2020-04-23

7.  BRCA1/2 variants and copy number alterations status in non familial triple negative breast cancer and high grade serous ovarian cancer.

Authors:  Fatima Zahra El Ansari; Farah Jouali; Rim Fekkak; Joaira Bakkach; Naima Ghailani Nourouti; Amina Barakat; Mohcine Bennani Mechita; Jamal Fekkak
Journal:  Hered Cancer Clin Pract       Date:  2022-08-19       Impact factor: 2.164

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.